Want to see CABA full AI Analyst Report?
CABA Stock Chart & Stats
$3.44
-$0.36(-13.38%)
At close: 4:00 PM EST
$3.44
-$0.36(-13.38%)
Day’s Range― - ―
52-Week Range$1.26 - $4.23
Previous CloseN/A
Volume846.62K
Average Volume (3M)5.77M
Market Cap
$435.36M
Enterprise Value$211.16
Total Cash (Recent Filing)$116.64M
Total Debt (Recent Filing)$26.45M
Price to Earnings (P/E)―
Beta4.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding163,054,800
10 Day Avg. Volume5,567,582
30 Day Avg. Volume5,770,087
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.75Price Target Upside357.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress & Registrational PathCabaletta has advanced rese-cel into defined registrational pathways across multiple autoimmune indications, including a planned SSc single-arm study and myositis cohorts toward a 2027 BLA. That structured regulatory path materially increases the chance of a durable commercialization route and expands addressable markets.
Manufacturing ScalabilityDemonstrating comparable biology from automated manufacturing is a durable operational advantage for a cell therapy developer. Automation supports reproducibility, lower per-dose variability and potential cost reductions, which are critical for commercial scale, margin sustainability and broader patient access.
Improved Runway & Strategic InvestorsThe sizable equity raise materially extends near-term funding and reduces immediate liquidity stress, while participation by strategic and institutional investors provides validation and potential partnership channels. This improves the company's ability to advance registrational studies and manufacturing readiness over the medium term.
Bears Say
Pre-revenue With Heavy Cash BurnCabaletta's lack of commercial revenue and large, accelerating cash burn create structural financing dependence. Sustained negative operating cash flow forces repeated capital raises, heightens dilution risk, and places persistent pressure on timelines for clinical advancement and commercial preparedness absent durable revenue sources.
Eroding Capital BaseThe steady decline in equity and assets reflects that the company is consuming its capital base to fund R&D. A smaller balance sheet reduces financial flexibility to absorb trial setbacks, slows optionality for partnerships or commercialization investments, and increases the likelihood further financing will be needed under less favorable terms.
Dilution & Financing Flexibility RiskDoubling authorized shares structurally increases the firm's capacity to issue equity, which, combined with ongoing cash burn, raises the realistic probability of meaningful dilution for existing shareholders. While it aids flexibility for deals and capital raises, it represents a persistent governance and ownership risk over time.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio, Inc.’s price range in the past 12 months?
Cabaletta Bio, Inc. lowest stock price was $1.26 and its highest was $4.23 in the past 12 months.
What is Cabaletta Bio, Inc.’s market cap?
Cabaletta Bio, Inc.’s market cap is $435.36M.
When is Cabaletta Bio, Inc.’s upcoming earnings report date?
Cabaletta Bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 19 days.
How were Cabaletta Bio, Inc.’s earnings last quarter?
Cabaletta Bio, Inc. released its earnings results on May 14, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.01.
Is Cabaletta Bio, Inc. overvalued?
According to Wall Street analysts Cabaletta Bio, Inc.’s price is currently Undervalued.
Does Cabaletta Bio, Inc. pay dividends?
Cabaletta Bio, Inc. does not currently pay dividends.
What is Cabaletta Bio, Inc.’s EPS estimate?
Cabaletta Bio, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Cabaletta Bio, Inc. have?
Cabaletta Bio, Inc. has 163,054,800 shares outstanding.
What happened to Cabaletta Bio, Inc.’s price movement after its last earnings report?
Cabaletta Bio, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went up 0.557%.
Which hedge fund is a major shareholder of Cabaletta Bio, Inc.?
Currently, no hedge funds are holding shares in CABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cabaletta Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (357.85% Upside)
$15.75 (357.85% Upside)
Blogger Sentiment
Bullish
CABA Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 61.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.98%
12-Months-Change
Fundamentals
Return on Equity
-131.58%
Trailing 12-Months
Asset Growth
-10.29%
Trailing 12-Months
Company Description
Cabaletta Bio, Inc.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$15.75
▲(357.85% Upside)
Technical Analysis
Tonix Pharma
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Entrada Therapeutics Inc
―
Ownership Overview
1.04% Insiders
9.86% Mutual Funds
<0.01% Other Institutional Investors
75.73% Public Companies and
Individual Investors